Educational resources

Final version - GiP supplement (print version)

Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care

Commissioned by Boehringer Ingelheim Limited

This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103451 Date of preparation: January 2021

Biosimilar insulin WPG

Guideline for the managed introduction of biosimilar basal insulin

Supported by an educational grant from Mylan

This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.